Clinical Trials Logo

Zika Virus Infection clinical trials

View clinical trials related to Zika Virus Infection.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05469802 Withdrawn - Healthy Volunteers Clinical Trials

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.

NCT ID: NCT03776695 Withdrawn - Clinical trials for Treatment of Acute Zika Virus Infection

Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients

Start date: October 9, 2018
Phase: Phase 1
Study type: Interventional

Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti. ZIKV is a growing public health problem, rapidly spreading throughout the continents since the first epidemic was reported in the French Polynesian islands. Currently, there are several ZIKV vaccine candidates in clinical trials. However, no ZIKV therapy (biologic or small molecule) has advanced to clinical trials. Tyzivumab will be the first therapeutic in the world, specifically targeting ZIKV, to enter clinical trials. This is a Phase 1, time-lagged, parallel-group, randomized, placebo-controlled, single-blind, single ascending dose, Tyzivumab, ZIKV monoclonal antibody (mAb), study to be conducted in ZIKV polymerase chain reaction (PCR) positive patients. Tyzivumab will be administered once through single IV infusion over 30 minutes. Total duration of study participation is estimated at approximately 85 days from the date of screening. Post-trial monitoring through weekly telephone calls will continue from Day 85 post-dose onwards for another three (3) more months. The main objective of this study is to evaluate the safety of Tyzivumab in acutely infected adult patients. Assessment of time taken to achieve negative ZIKV isolation from acute ZIKV infected subjects' blood will be the study's secondary objectives.

NCT ID: NCT03229421 Withdrawn - Clinical trials for Zika Virus Symptoms and the Associated Exanthema

Dermatologic Manifestations of Zika Virus

DMZV
Start date: July 6, 2017
Phase:
Study type: Observational

The purpose of this study is to determine whether any diagnostic patterns exist in the symptom presentation of Zika Virus.

NCT ID: NCT03204409 Withdrawn - Clinical trials for Zika Virus Infection

ZIKAlliance Natural History Study

ZIKAllianceNH
Start date: April 1, 2018
Phase:
Study type: Observational

Study to enroll up to 1000 adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h) in designated clinics in the State of Sao Paulo, Brazil.